Investment Analysts’ Recent Ratings Changes for Sensei Biotherapeutics (FTH)

A number of firms have modified their ratings and price targets on shares of Sensei Biotherapeutics (NASDAQ: FTH) recently:

• 8/11/2026 – Sensei Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
• 8/8/2026 – Sensei Biotherapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/4/2026 – Sensei Biotherapeutics is now covered by JonesTrading. They set a “buy” rating and a $55.00 price target on the stock.
• 7/31/2026 – Sensei Biotherapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $56.00 price target on the stock.
• 7/28/2026 – Sensei Biotherapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $60.00 price target on the stock.
• 7/20/2026 – Sensei Biotherapeutics is now covered by Citizens Jmp. They set an “outperform” rating and a $51.00 price target on the stock.
• 7/16/2026 – Sensei Biotherapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 6/26/2026 – Sensei Biotherapeutics is now covered by Robert W. Baird. They set an “outperform” rating and a $57.00 price target on the stock.
• 6/25/2026 – Sensei Biotherapeutics was upgraded by Robert W. Baird to “strong-buy”.
• 6/22/2026 – Sensei Biotherapeutics is now covered by HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.

Insider Buying and Selling at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 49,494 shares of company stock valued at $1,188,822 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.